Brief: Cipher pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
12/07/2016 12:00
July 12 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO
* Cipher Pharmaceuticals announces ozenoxacin accepted for
review by Health Canada
* Cipher Pharmaceuticals Inc says that its new drug
submission for ozenoxacin has been accepted for review by Health
Canada
Source text for Eikon: ID:nPn8DjL6ja
Further company coverage: CPH.TO
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million